FDA Approves Italfarmaco SpA’s Duvyzat for Duchenne Muscular Dystrophy

Duvyzat (givinostat) is histone deacetylase inhibitor that was previously granted priority review, orphan drug designation, and rare pediatric disease designation by the FDA for patients 6 years of age and older with Duchenne muscular dystrophy.